CO6362050A2 - Vectores de terapia de gen y desaminasas citosina - Google Patents

Vectores de terapia de gen y desaminasas citosina

Info

Publication number
CO6362050A2
CO6362050A2 CO11050300A CO11050300A CO6362050A2 CO 6362050 A2 CO6362050 A2 CO 6362050A2 CO 11050300 A CO11050300 A CO 11050300A CO 11050300 A CO11050300 A CO 11050300A CO 6362050 A2 CO6362050 A2 CO 6362050A2
Authority
CO
Colombia
Prior art keywords
desaminases
citamine
vectors
gen therapy
gen
Prior art date
Application number
CO11050300A
Other languages
English (en)
Spanish (es)
Inventor
Harry E Gruber
Douglas J Jolly
Christopher R Logg
Omar D Perez
Original Assignee
Tocagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tocagen Inc filed Critical Tocagen Inc
Publication of CO6362050A2 publication Critical patent/CO6362050A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO11050300A 2008-09-26 2011-04-25 Vectores de terapia de gen y desaminasas citosina CO6362050A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10066608P 2008-09-26 2008-09-26
US12061808P 2008-12-08 2008-12-08
US18682309P 2009-06-13 2009-06-13

Publications (1)

Publication Number Publication Date
CO6362050A2 true CO6362050A2 (es) 2012-01-20

Family

ID=42060421

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11050300A CO6362050A2 (es) 2008-09-26 2011-04-25 Vectores de terapia de gen y desaminasas citosina

Country Status (18)

Country Link
US (3) US8722867B2 (cg-RX-API-DMAC7.html)
EP (4) EP2346995B1 (cg-RX-API-DMAC7.html)
JP (6) JP5684130B2 (cg-RX-API-DMAC7.html)
KR (3) KR102025502B1 (cg-RX-API-DMAC7.html)
CN (4) CN102227501B (cg-RX-API-DMAC7.html)
AU (1) AU2009303690B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0919113A2 (cg-RX-API-DMAC7.html)
CA (1) CA2738472A1 (cg-RX-API-DMAC7.html)
CO (1) CO6362050A2 (cg-RX-API-DMAC7.html)
DK (1) DK2346995T3 (cg-RX-API-DMAC7.html)
EA (2) EA027693B1 (cg-RX-API-DMAC7.html)
ES (2) ES2709481T3 (cg-RX-API-DMAC7.html)
IL (3) IL211847A (cg-RX-API-DMAC7.html)
MX (3) MX2011003039A (cg-RX-API-DMAC7.html)
MY (1) MY156333A (cg-RX-API-DMAC7.html)
NZ (1) NZ592070A (cg-RX-API-DMAC7.html)
WO (2) WO2010045002A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102115B (cg-RX-API-DMAC7.html)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115290B1 (en) 1998-10-01 2009-03-04 University of Southern California Retroviral gene delivery system and methods of use
CA2724740C (en) 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
MX2011003039A (es) * 2008-09-26 2011-08-15 Tocagen Inc Vectores de terapia genica y citosina deaminasas.
CN102459616A (zh) 2009-06-17 2012-05-16 托卡根公司 复制型逆转录病毒载体的生产细胞
CA2836977A1 (en) * 2010-06-06 2011-12-15 Benjamin R. Tenoever Recombinant rna viruses and uses thereof
ES2655500T3 (es) 2010-07-16 2018-02-20 Tocagen Inc. Detección de retrovirus
US9669049B2 (en) 2010-10-31 2017-06-06 Tocagen Inc. Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
US20140178854A1 (en) 2010-10-31 2014-06-26 Tocagen Inc. Antisera assays for mlv related viruses in humans and other mammals
CN107488233A (zh) * 2011-06-02 2017-12-19 台北荣民总医院 治疗感染性与恶性疾病的标靶化学治疗药物的形成方法
KR101554678B1 (ko) * 2012-10-19 2015-09-21 영남대학교 산학협력단 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
CA2910311A1 (en) * 2012-11-15 2014-05-22 Esperance Pharmaceuticals, Inc. Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
WO2014201449A2 (en) 2013-06-15 2014-12-18 Tocagen Inc. Immunosuppressive components associated with retroviral replicating vectors
CN105579581A (zh) * 2013-08-05 2016-05-11 托卡根公司 具有优化的a凸出物的重组载体
CN103966260A (zh) * 2014-03-07 2014-08-06 山东农业大学 一种基于J亚群禽白血病病毒pol基因保守序列的siRNA重组干扰载体及其制备方法和应用
JP6894236B2 (ja) * 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
KR102508166B1 (ko) 2014-04-10 2023-03-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 세포 면역요법을 위한 방법 및 조성물
WO2015168102A2 (en) * 2014-04-28 2015-11-05 Board Of Regents, The University Of Texas System Prolonged protein stabilization by resveratrol
CN104557602B (zh) * 2015-01-07 2016-08-17 华东师范大学 三环二萜衍生物及其制备方法、及其在制备抗肿瘤药物中的应用
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
JP2018526007A (ja) 2015-09-04 2018-09-13 トカジェン インコーポレーテッド ２ａペプチドを含む組換えベクター
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
GB2572716B (en) 2016-11-29 2022-06-22 Articure Co Ltd Gene Therapy Vector System and Prodrug Genes
CN107058314B (zh) * 2016-11-30 2020-09-04 暨南大学 一种启动子及其应用
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
LT3645719T (lt) 2017-06-30 2022-05-25 Inscripta, Inc. Automatinio ląstelių apdorojimo būdai, moduliai, priemonės ir sistemos
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US20200224220A1 (en) * 2017-07-14 2020-07-16 Oncorus, Inc. Encapsulated polynucleotides and methods of use
US20190191975A1 (en) * 2017-12-27 2019-06-27 Ethicon Llc Fluorescence imaging in a light deficient environment
US20200392512A1 (en) * 2018-02-26 2020-12-17 Ablynx N.V. Nucleotide sequences encoding peptide linkers
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
CN110396504A (zh) * 2018-04-25 2019-11-01 江苏省原子医学研究所 一种具有肿瘤靶向性的重组痘苗病毒及其制备方法、用途
US10533152B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
EP3653716A1 (en) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
EP3947691A4 (en) 2019-03-25 2022-12-14 Inscripta, Inc. SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
EP3953477A4 (en) 2019-06-06 2022-06-22 Inscripta, Inc. HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING
US11389066B2 (en) 2019-06-20 2022-07-19 Cilag Gmbh International Noise aware edge enhancement in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US20200397239A1 (en) 2019-06-20 2020-12-24 Ethicon Llc Offset illumination of a scene using multiple emitters in a fluorescence imaging system
US11237270B2 (en) 2019-06-20 2022-02-01 Cilag Gmbh International Hyperspectral, fluorescence, and laser mapping imaging with fixed pattern noise cancellation
US11516387B2 (en) 2019-06-20 2022-11-29 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US11096565B2 (en) 2019-06-20 2021-08-24 Cilag Gmbh International Driving light emissions according to a jitter specification in a hyperspectral, fluorescence, and laser mapping imaging system
US12013496B2 (en) 2019-06-20 2024-06-18 Cilag Gmbh International Noise aware edge enhancement in a pulsed laser mapping imaging system
US11284783B2 (en) 2019-06-20 2022-03-29 Cilag Gmbh International Controlling integral energy of a laser pulse in a hyperspectral imaging system
US11360028B2 (en) 2019-06-20 2022-06-14 Cilag Gmbh International Super resolution and color motion artifact correction in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US12126887B2 (en) 2019-06-20 2024-10-22 Cilag Gmbh International Hyperspectral and fluorescence imaging with topology laser scanning in a light deficient environment
US12181412B2 (en) 2019-06-20 2024-12-31 Cilag Gmbh International Minimizing image sensor input/output in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US12357162B2 (en) 2019-06-20 2025-07-15 Cilag Gmbh International Videostroboscopy of vocal cords with a hyperspectral, fluorescence, and laser mapping imaging system
US12440085B2 (en) 2019-06-20 2025-10-14 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed laser mapping imaging system
US11012599B2 (en) 2019-06-20 2021-05-18 Ethicon Llc Hyperspectral imaging in a light deficient environment
US10952619B2 (en) 2019-06-20 2021-03-23 Ethicon Llc Hyperspectral and fluorescence imaging and topology laser mapping with minimal area monolithic image sensor
TWI883032B (zh) 2019-08-12 2025-05-11 中國大陸商北京恩瑞尼生物科技股份有限公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
KR102281858B1 (ko) 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
CN114829607A (zh) 2019-12-18 2022-07-29 因思科瑞普特公司 用于体内检测核酸引导的核酸酶编辑的细胞的Cascade/dCas3互补测定
US11225674B2 (en) 2020-01-27 2022-01-18 Inscripta, Inc. Electroporation modules and instrumentation
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN111944810B (zh) * 2020-07-29 2022-05-27 中国农业大学 靶向敲除TNFα基因的sgRNA和敲除TNFα基因的猪胚胎成纤维细胞系及其应用
US11299731B1 (en) 2020-09-15 2022-04-12 Inscripta, Inc. CRISPR editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
AU2021415461A1 (en) 2021-01-04 2023-08-17 Inscripta, Inc. Mad nucleases
WO2022150269A1 (en) 2021-01-07 2022-07-14 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
US20250243277A1 (en) 2021-10-07 2025-07-31 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas
AU2023262112A1 (en) 2022-04-29 2024-10-31 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
CN118697758B (zh) * 2024-05-31 2025-10-21 河北大学 miR-128-1-5p的应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5770428A (en) * 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
CA2160034C (en) 1993-04-06 2005-09-06 Maribeth V. Eiden Gibbon ape leukemia virus-based retroviral vectors
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
AU7971194A (en) 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
KR100507431B1 (ko) 1994-11-07 2005-12-21 휴먼 게놈 사이언시즈, 인코포레이티드 종양괴사인자-γ
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
EP2017337A1 (en) 1995-04-27 2009-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
ATE397660T1 (de) 1996-08-16 2008-06-15 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
EP0961831B1 (en) 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Human endokine alpha
WO1998013487A1 (en) 1996-09-27 1998-04-02 Maxygen, Inc. Methods for optimization of gene therapy by recursive sequence shuffling and selection
AU731553B2 (en) 1996-10-25 2001-04-05 Human Genome Sciences, Inc. Neutrokine alpha
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
CA2276064C (en) 1997-01-17 2013-12-17 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1998032856A1 (en) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
PL335860A1 (en) 1997-03-18 2000-05-22 Novo Nordisk As Method of in vitro constructing a dna library
EP0996718B1 (en) 1997-03-18 2008-12-24 Novozymes A/S Method for constructing a library using dna shuffling
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
EP1003767A4 (en) 1997-05-30 2003-01-02 Human Genome Sciences Inc TR10 RECEPTOR OF HUMAN TUMOR NECROSIS FACTOR
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
AU1334999A (en) 1997-10-20 1999-05-10 Universita Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
AU1449499A (en) 1997-10-31 1999-05-24 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
DK2270234T3 (da) 1997-12-08 2013-06-03 California Inst Of Techn Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
WO1999041383A1 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Antigen library immunization
AU2674299A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
CA2327444A1 (en) 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
GB9810752D0 (en) 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
AU4089899A (en) 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
CA2331926C (en) 1998-06-29 2013-09-10 Phylos, Inc. Methods for generating highly diverse libraries
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
FR2782323B1 (fr) 1998-08-12 2002-01-11 Proteus Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues
JP2002537758A (ja) 1998-09-29 2002-11-12 マキシジェン， インコーポレイテッド コドン変更された遺伝子のシャッフリング
EP1115290B1 (en) * 1998-10-01 2009-03-04 University of Southern California Retroviral gene delivery system and methods of use
US6899871B2 (en) 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
EP1151409A1 (en) 1999-01-18 2001-11-07 Maxygen, Inc. Methods of populating data stuctures for use in evolutionary simulations
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
EP1108781A3 (en) 1999-01-19 2001-09-12 Maxygen, Inc. Method for making character strings, polynucleotides and polypeptides
WO2000066758A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
GB2368846B (en) 1999-07-08 2004-08-25 Univ California Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
US8163893B2 (en) 2006-02-15 2012-04-24 The Regents Of The University Of Caifornia Pseudotyped retroviral vectors and methods of use thereof
AU7521500A (en) 1999-11-30 2001-06-12 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2001241939A1 (en) 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
WO2002022663A2 (en) 2000-09-18 2002-03-21 Maxygen, Inc. Stress resistant retroviruses
US20030003565A1 (en) * 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
WO2002061104A2 (en) 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
AU2002326906C1 (en) * 2001-09-13 2009-01-29 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US20030219410A1 (en) 2002-02-01 2003-11-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated to PODs
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US20040068762A1 (en) 2002-07-17 2004-04-08 Attar Ricardo M. Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements
WO2004022761A1 (en) * 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
CN1826410B (zh) 2003-07-21 2011-10-26 特兰斯吉恩股份有限公司 具有改良的胞嘧啶脱氨酶活性的多肽
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
RU2007114111A (ru) 2004-11-04 2008-12-10 Пфайзер Продактс Инк. (Us) Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы
CN101065492A (zh) * 2004-11-24 2007-10-31 纳诺非科特有限公司 病毒载体
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
WO2006127980A2 (en) 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
JP2007054069A (ja) * 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
WO2007036233A2 (en) * 2005-09-30 2007-04-05 Zgene A/S Dekkera/brettanomyces cytosine deaminases and their use
JP5976986B2 (ja) * 2005-10-01 2016-08-24 チャールズ スタウト， 調節可能な融合プロモーター
WO2007044483A2 (en) 2005-10-07 2007-04-19 President And Fellows Of Harvard College Attenuated vaccines for non-segmented negative sense rna viruses
EP1795596A1 (en) * 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
EP2468895B1 (en) * 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
US8557971B2 (en) 2006-03-17 2013-10-15 Aarhus Universitet Chimeric viral envelopes
JP6092497B2 (ja) * 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
DK2048955T3 (da) * 2006-07-21 2013-09-02 California Inst Of Techn Målrettet gen-tilførsel til dendrit-cellevaccination
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
CA2724740C (en) 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
MX2011003039A (es) * 2008-09-26 2011-08-15 Tocagen Inc Vectores de terapia genica y citosina deaminasas.
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102459616A (zh) * 2009-06-17 2012-05-16 托卡根公司 复制型逆转录病毒载体的生产细胞
US8993837B2 (en) 2010-08-13 2015-03-31 Pioneer Hi-Bred International, Inc Chimeric promoters and methods of use

Also Published As

Publication number Publication date
EA201790824A2 (ru) 2017-08-31
ZA201102115B (en) 2012-07-25
JP2017018121A (ja) 2017-01-26
MY156333A (en) 2016-02-15
CN102227503A (zh) 2011-10-26
CN102227501A (zh) 2011-10-26
EP3460061A1 (en) 2019-03-27
US8722867B2 (en) 2014-05-13
DK2346995T3 (en) 2019-02-11
JP2015119712A (ja) 2015-07-02
EA201170492A1 (ru) 2011-10-31
NZ592070A (en) 2012-07-27
MX357418B (es) 2018-07-09
KR20110063673A (ko) 2011-06-13
KR101724162B1 (ko) 2017-04-07
JP6523224B2 (ja) 2019-05-29
WO2010045002A2 (en) 2010-04-22
JP5684130B2 (ja) 2015-03-11
JP2019141088A (ja) 2019-08-29
JP2015186479A (ja) 2015-10-29
KR20160079149A (ko) 2016-07-05
IL264214A (en) 2019-02-28
KR102025502B1 (ko) 2019-09-25
EP3502256A2 (en) 2019-06-26
IL211847A0 (en) 2011-06-30
JP6062485B2 (ja) 2017-01-18
EA027693B1 (ru) 2017-08-31
JP5992548B2 (ja) 2016-09-14
CN102227503B (zh) 2015-10-21
ES2709481T3 (es) 2019-04-16
WO2010045002A3 (en) 2010-08-26
JP5771147B2 (ja) 2015-08-26
KR101870056B1 (ko) 2018-07-23
CN105624193B (zh) 2021-07-13
EP3502256A3 (en) 2019-09-25
AU2009303690A1 (en) 2010-04-22
CN105274125A (zh) 2016-01-27
JP2012503987A (ja) 2012-02-16
WO2010036986A3 (en) 2010-07-01
IL264214B (en) 2020-01-30
EP2344648B1 (en) 2018-11-14
US20190185821A1 (en) 2019-06-20
BRPI0919113A2 (pt) 2016-08-09
IL211847A (en) 2016-11-30
ES2706899T3 (es) 2019-04-01
CN105624193A (zh) 2016-06-01
CN102227501B (zh) 2016-11-16
US20110217267A1 (en) 2011-09-08
EP2346995A4 (en) 2011-12-07
US10035983B2 (en) 2018-07-31
EP2344648A2 (en) 2011-07-20
MX2018008440A (es) 2021-06-15
US20140242033A1 (en) 2014-08-28
KR20180069131A (ko) 2018-06-22
EP2346995B1 (en) 2018-11-07
MX2011003039A (es) 2011-08-15
WO2010036986A2 (en) 2010-04-01
AU2009303690B2 (en) 2014-06-19
EP2346995A2 (en) 2011-07-27
JP2012503986A (ja) 2012-02-16
EP2344648A4 (en) 2012-03-14
IL248833A0 (en) 2017-01-31
CA2738472A1 (en) 2010-04-22
IL248833B (en) 2019-01-31
EA201790824A3 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
CO6362050A2 (es) Vectores de terapia de gen y desaminasas citosina
MX2011011949A (es) Metodos para el tratamiento de enfermedades mediante el uso de un cambiador epimetabólico (coenzima q10).
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
EP4559918A3 (en) Glucosylceramide synthase inhibitors
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
GB0920703D0 (en) Compositions containing satiogens and methods of use
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MY159971A (en) Multipotent/pluripotent cells and methods
IN2014CN02518A (cg-RX-API-DMAC7.html)
IN2012DN02485A (cg-RX-API-DMAC7.html)
BR112014027227A2 (pt) modificação alvejada de malato desidrogenase
WO2011139628A8 (en) Generation of anterior foregut endoderm from pluripotent cells
MX2016005824A (es) Metodo de cultivo celular.
ATE549638T1 (de) 13c-mr-bildgebung oder spektroskopie von zelltod
WO2011097242A3 (en) Methods of isolating and culturing mesenchymal stem cells
WO2010065546A3 (en) MAINTENANCE/EXPANSION OF HSCs
UA104298C2 (ru) Векторы для генной терапии и цитозиндезаминазы
WO2008097828A8 (en) Method for isolating mesenchymal stromal cells
WO2010052580A3 (en) Hsc self-renewal
IL209604A (en) Isolated cell populations, methods for their creation and use in the treatment of central nervous system diseases
WO2011110838A3 (en) Therapeutic treatments and screening methods using p63
AR090006A1 (es) Diagnostico y tratamientos relacionados con la inhibicion de th2
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
AU2012208993A1 (en) Gondola_mop

Legal Events

Date Code Title Description
FC Application refused